Establishment of ELISA on 384-well microplate for AFP, CEA, CA 19-9, CA 15-3, CA 125, and PSA-ACT: Higher sensitivity and lower reagent cost

被引:19
|
作者
Wu, TL
Sun, YC
Chang, PY
Tsao, KC
Sun, CF
Wu, JT
机构
[1] Univ Utah, ARUP, Hlth Sci Ctr, Salt Lake City, UT 84108 USA
[2] Univ Utah, Dept Pathol, Hlth Sci Ctr, Salt Lake City, UT 84108 USA
[3] Chang Gung Mem Hosp, Dept Pathol, Taipei 10591, Taiwan
关键词
tumor marker; ELISA; 384-well microplate; 96-well microplate;
D O I
10.1002/jcla.10104
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The 384-well microplate contains four times as many wells as the regular 96-well microplate. Establishing enzyme linked immunosorbent assay (ELISA) on 384-well microplate should lead to savings in reagents and specimens. To determine that ELISAs on 384-well microplate have acceptable assay precision, ELISAs for tumor markers, including AFP, PSA-ACT, CEA, CA 125, CA 15-3, and CA 19-9, were compared to the same ELISAs established on 96-well microplate. We found that ELISAs established on 384-well microplate had similar sensitivity and covered similar concentration ranges as ELISAs on 96-well microplate. All within-day and day-to-day precisions for the 384-ELISA had %CV less than 10%. Compared to ELISA on 96-well microplate, 384-ELISA used less reagents, less specimen, and exhibited approximately a two-fold increase in sensitivity. Overall cost of the 384-384-ELISA was also greatly reduced. Our results suggest that 384-ELISA is suitable for use in routine clinical laboratories. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:241 / 246
页数:6
相关论文
共 41 条
  • [41] Evaluation of the analytical and clinical performance of the access® BR-Monitor (CA 15-3 antigen), OV-Monitor (CA 125 antigen), and GI-Monitor (CA 19-9 antigen) assays on Beckman Coulter's UniCel® DxI 800 immunoassay system:: an European multicenter study
    Stieber, P.
    Molina, R.
    Gion, M.
    Gressner, A.
    Troalen, F.
    Holdenrieder, S.
    Auge, J. M.
    Zancan, M.
    Wycislo, M.
    Jarrige, V
    TUMOR BIOLOGY, 2006, 27